XML 48 R33.htm IDEA: XBRL DOCUMENT v3.26.1
EQUITY (Tables)
 12 Months Ended
Dec. 31, 2025
Equity [Abstract]  
SCHEDULE OF ISSUANCE OF WARRANTS TO PURCHASE COMMON STOCK

As of December 31, 2025, the Company had outstanding warrants to purchase an aggregate of 26,920,508 shares of common stock, as follows:

 

   Number of
underlying
Common stock		   Exercise price   Expiration date
Series G Warrants   1,092,344   $10.230   February 8, 2026
Series J Warrants   12,914,086   $1.3827   -*
Series K Warrants   12,914,078   $1.3827   -*
Total Warrants   26,920,508         

 

  *

The Series J Warrants and Series K Warrants have a term of the earlier of (i) May 15, 2028 and (ii) (A) in the case of the Series J Warrants, 20 trading days following the Company’s announcement of receipt of FDA approval for the SwitchGuard and CGuard Prime 80 cm and (B) in the case on the Series K Warrants, 20 trading days following the end of the fourth fiscal quarter after the fiscal quarter in which the first commercial sales of CGuard Prime in the U.S. begins.

 

During the years ended December 31, 2025 and 2024, a total of 433,878 and 213,458 warrants expired unexercised, respectively.
SCHEDULE OF STOCK OPTIONS GRANTED

 

   Year ended December 31 
   2025 
   Number of
options		  

Weighted average

exercise price

 
Outstanding - beginning of the year   2,154,143    2.76 
Granted   1,119,127    2.63 
Forfeited   (79,541)   3.25 
Outstanding- end of year   3,193,729    2.70 
Exercisable at the end of the year   1,612,755    2.79 

 

 

INSPIREMD, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

 

3)Stock Options – Non-Employees

 

    The following table summarizes information about stock options granted to non-employees:

 

   Year ended December 31 
   2025 
   Number of
options		   Weighted average
exercise price		 
Outstanding - beginning of the year   916,669    2.10 
Granted   -    - 
Outstanding - end of year   916,669    2.10 
Exercisable at the end of the year   639,003    2.19 

 

4)Restricted Stock – Employees and non-employees

 

    The following table summarizes information about restricted stock granted to employees and non-employees:

 

   Year ended
December 31		 
   2025 
    Number of
restricted stock		 
Outstanding - beginning of the year   4,073,966 
Granted   3,933,081 
Forfeited   (256,170)
Vested   (2,573,691)
Outstanding - end of the year   5,177,186 

 

5)Restricted Stock Units (RSUs) – Employees

 

    The following table summarizes information about RSUs granted to employees:

 

   Year ended December 31 
   2025 
   Number of RSUs 
Outstanding - beginning of the year   1,845,727 
Granted   558,417 
Outstanding - end of the year   2,404,144 
SCHEDULE OF ADDITIONAL INFORMATION ABOUT ALL OPTIONS OUTSTANDING AND EXERCISABLE

 

    Outstanding as of December 31, 2025 

Exercise price

   Options outstanding   Weighted average
remaining
contractual life
(years)		   Options exercisable 
$1.15-3.14    3,772,718    6.98    1,926,991 
$3.30-4.12    181,352    5.28    168,439 
$4.95-10.05    152,275    4.27    152,275 
$16.50    4,053    4.01    4,053 
      4,110,398    6.80    2,251,758 
SCHEDULE OF FAIR VALUE OF OPTIONS GRANTED TO EMPLOYEES

 

    Year ended December 31 
    2025    2024 
Expected life   2; 5.5-6.5    5.125-10 years 
Risk-free interest rates   3.45% - 3.64%; 3.64%-4.68%    3.93%-4.44% 
Volatility   38.69%- 49.34%; 75.74%-92.69%    91.82%-119.38% 
Dividend yield   -    - 
SCHEDULE OF ALLOCATION OF TOTAL SHARE-BASED COMPENSATION EXPENSE

 

   Year ended December 31 
   2025   2024 
   ($ in thousands) 
Cost of revenues  $218   $256 
Research and development   2,559    2,412 
Sales and marketing   1,888    1,025 
General and administrative   7,667    6,445 
   $12,332   $10,138